Kamil R Kranc

9PUBLICATIONS
88CO-AUTHORS
Haematological tumoursMolecular targetsHaematologyMedical molecular engineering of nucleic acids and proteinsCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Aug 12, 2026
RNA terminal uridylyl transferases are druggable vulnerabilities in AML but are dispensable for normal hematopoiesis.

|Aug 26, 2024
Stearoyl-CoA desaturase inhibition is toxic to acute myeloid leukemia displaying high levels of the de novo fatty acid biosynthesis and desaturation.

Vilma Dembitz, Hannah Lawson, Richard Burt

|Apr 18, 2024
The selective prolyl hydroxylase inhibitor IOX5 stabilizes HIF-1α and compromises development and progression of acute myeloid leukemia.

Hannah Lawson, James P Holt-Martyn, Vilma Dembitz

|Apr 18, 2024
HOXA9 and β-catenin safeguard HSC integrity.

Christopher Mapperley, Kamil R Kranc

|Apr 14, 2023
Mannose metabolism inhibition sensitizes acute myeloid leukaemia cells to therapy by driving ferroptotic cell death.

Keith Woodley, Laura S Dillingh, George Giotopoulos

|Aug 09, 2022
MYC sensitises cells to apoptosis by driving energetic demand.

Joy Edwards-Hicks, Huizhong Su, Maurizio Mangolini

Pageof 2

Frequent Collaborators

4 joint publications

Andrew J Finch

3 joint publications

Vilma Dembitz

3 joint publications

Jozef Durko

3 joint publications

Christopher Mapperley